PRESS RELEASE 2021

Women in India are the first in the world to receive new heat-stable carbetocin formulation to prevent excessive bleeding after childbirth

By celia in PRESS RELEASE 2021 on 26 July 2021

After nearly a decade of public-private collaboration, Ferring Pharmaceuticals today announces the first use of heat-stable carbetocin (Carbetocin Ferring) for the prevention of excessive bleeding after birth, known as postpartum haemorrhage (PPH)…

!

Ferring Pharmaceuticals announces changes to Board of Directors

By celia in PRESS RELEASE 2021 on 01 July 2021

Ferring Pharmaceuticals announced today that Frederik Paulsen is stepping down from his role as Chairman of the Board of Directors and transitioning to the role of Honorary Chairman. Lars Rebien Sørensen is appointed Chairman of the Board of Directors…

!

Ferring presents new data at ESHRE 2021 supporting the use of Rekovelle® (follitropin delta) for individualized fertility treatment

By celia in PRESS RELEASE 2021 on 29 June 2021

New data, presented today at the 37th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE), show a comparable ongoing pregnancy rate of 31.3% with the individualised dosing regimen of Rekovelle, compared to 25.7% with follitropin alfa…

!

Ferring and Rebiotix Present Positive Interim Phase 3 Results from Open-Label Study of Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW)

By celia in PRESS RELEASE 2021 on 22 May 2021

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, announced today the first presentation of interim data from a Phase 3 open-label study showing strong trends in efficacy and safety for investigational microbiota-based live biotherapeutic RBX2660…

!

Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection

By celia in PRESS RELEASE 2021 on 21 May 2021

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today presented results from the pivotal Phase 3 PUNCH™ CD3 clinical trial, demonstrating superior efficacy and consistent safety of single-dose RBX2660 in reducing recurrence of Clostridioides difficile infection…

!

Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW) 2021

By celia in PRESS RELEASE 2021 on 13 May 2021

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced that Phase 3 data evaluating its investigational microbiota-based live biotherapeutic RBX2660 for reduction of recurrent Clostridioides difficile (C. difficile) infection will be presented…

!

Ferring appoints Jan Lundberg to Group Board

By caju in PRESS RELEASE 2021 on 18 February 2021

Ferring Pharmaceuticals announced today that Jan Lundberg has been appointed to the Ferring Group Board, effective January 2021, as a non-executive director and Chairman of the Research and Development Committee, following the retirement of John Patterson…

!

Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health

By celia in PRESS RELEASE 2021 on 17 February 2021

Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive…

!